NOrthwestern Tempus AI-enaBLed Electrocardiography (NOTABLE) Trial
NCT06511505
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to determine if a machine learning/artificial intelligence (AI)-based electrocardiogram (ECG) algorithm (rECHOmmend and ECG-AF) can identify undiagnosed cardiovascular disease in patients. It will also examine the safety and effectiveness of using this AI-based tool in a clinical setting. The main questions it aims to answer are: Can the AI-based ECG algorithm improve the detection of atrial fibrillation and structural heart disease? How does the use of this algorithm affect clinical decision-making and patient outcomes?
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Atrial Fibrillation
- Cardiovascular Diseases
- Arrhythmia
- Valvular Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Northwestern University
- Last updated on ClinicalTrials.gov
- August 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 1
- Northwestern University · Chicago, IL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.